PCRX (Pacira BioSciences) Stock Based Compensation: $56.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCRX Pacira BioSciences Inc PCRX
69 GF Score
Price $24.43
GF Value $29.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Stock Based Compensation?

Pacira BioSciences PCRX -2.36% 69 Stock Based Compensation is $56.0 Mil as of Jun. 2026. GuruFocus rates PCRX with a GF Score™ of 69/100 and a GF Value™ of $29.11 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Pacira BioSciences's Stock Based Compensation for the three months ended in Jun. 2026 was $15.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $56.0 Mil.

Pacira BioSciences Stock Based Compensation Related Terms

Pacira BioSciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Stock Based Compensation Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.25 48.09 47.90 51.17 57.50

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.47 13.98 13.50 13.54 14.96
PCRX
69GF Score
Pacira BioSciences Inc PCRX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.0 Mil.

What does a Stock Based Compensation of $56.0 Mil mean?
Pacira BioSciences (PCRX) has a Stock Based Compensation of $56.0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pacira BioSciences and its competitors.
Is Pacira BioSciences' Stock Based Compensation too high?
Pacira BioSciences' current Stock Based Compensation is $56.0 Mil. Overall, Pacira BioSciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Stock Based Compensation compare to ALVO and BIOA?
Pacira BioSciences' Stock Based Compensation of $56.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pacira BioSciences and its competitors. Pacira BioSciences's current Stock Based Compensation is $56.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.11, compared to a current price of $24.43 — trading 16.1% below its estimated fair value. The current Stock Based Compensation is $56.0 Mil. Pacira BioSciences' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Stock Based Compensation is $56.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (PCRX) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of $24.43 is trading 16.1% below its estimated GF Value™ of $29.11. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for PCRX:

  • Stock Based Compensation: $56.0 Mil
  • GF Value™: $29.11 vs. price of $24.43 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges 82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
69GF Score

Get the complete analysis for PCRX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.43
Price
$29.11
GF Value